Cardiac amyloidosis continues to get more and more attention at cardiology meetings. At Heart Failure 2026 in Spain, it was the topic of multiple studies, including one on the benefits of acoramidis.
Up to 30% of U.S. patients carry genetic variations that reduce the effectiveness of clopidogrel, an antiplatelet medication sold under the brand name Plavix.
This new catheter-based device for lymphatic drainage showed early potential to be an effective treatment option for acute decompensated heart failure.
The REVEAL study has been assessing the sensitivity and specificity of iodine 124 evuzamitide (I 124 evuzamitide), a PET agent capable of visualizing signs of cardiac amyloidosis on imaging.
Using an advanced MRI technique, experts were able to measure tissue susceptibility and detect subtle variances in iron levels throughout different regions of the brain associated with memory.
Evaluating LVDF with echocardiography or AI-powered electrocardiography can help identify individuals at an increased risk of developing atrial fibrillation, according to new data presented at the ASE 36th Annual Scientific Sessions.
Reuters reported that 500 institutions are linked to the proposals. In total, $50 million is up for grabs as part of HHS’ Autism Data Science Initiative.
When patients present with STEMI-related cardiogenic shock, treatment with the Impella CP appears to make a positive impact that lasts for at least a decade.
The U.S. Department of Health and Human Services is set to release a report this month outlining possible causes of autism spectrum disorder. The Wall Street Journal reports that it names “low folate levels and acetaminophen during pregnancy” as contributing factors.
The study, which will be funded by a $2.3 million grant from the U.S. Department of Defense, will harness the power of advanced MRI technology to visualize the brain in a way that has not previously been possible.
![A majority of medical devices involved in Class I recalls were never required by the U.S. Food and Drug Administration (FDA) to undergo premarket or postmarket clinical testing, according to new research published in Annals of Internal Medicine.[1]](/sites/default/files/styles/top_stories/public/2024-09/istock-1209664264.jpg.webp?itok=gQInU1vO)
